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Summary
Skeletal and cardiac muscle depend on high turnover of ATP made by mitochondria in order to contract efficiently. The
transcriptional coactivator PGC-1α has been shown to function as a major regulator of mitochondrial biogenesis and
respiration in both skeletal and cardiac muscle, but this has been based only on gain-of-function studies. Using genetic
knockout mice, we show here that, while PGC-1α KO mice appear to retain normal mitochondrial volume in both muscle
beds, expression of genes of oxidative phosphorylation is markedly blunted. Hearts from these mice have reduced mito-
chondrial enzymatic activities and decreased levels of ATP. Importantly, isolated hearts lacking PGC-1α have a diminished
ability to increase work output in response to chemical or electrical stimulation. As mice lacking PGC-1α age, cardiac
dysfunction becomes evident in vivo. These data indicate that PGC-1α is vital for the heart to meet increased demands
for ATP and work in response to physiological stimuli.Introduction
Living organisms must convert chemical energy into mechani-
cal work. Muscle is a specialized tissue devoted primarily to
this task. The energy needs in muscle are quite high and must
be precisely regulated. Nowhere is this more true than in the
heart, where work is generated unfailingly for decades and
where energy consumption is higher than in any other organ.
The availability of energy in skeletal and cardiac muscle can be
significantly altered in both health and disease. Chronic exer-
cise in skeletal muscle, for example, stimulates a switching
from predominantly glycolytic to more oxidative fibers, which
contain more mitochondria and are resistant to fatigue (Booth
and Thomason, 1991). Conversely, aberrations in energy pro-
duction are seen in such diverse muscular diseases as muscu-
lar dystrophies, mitochondrial myopathies (Kelly and Strauss,
1994; Wallace, 1992), and chronic congestive heart failure
(Ingwall, 2002; Ingwall and Weiss, 2004). How these defects
come about remains incompletely understood, in particular at
the level of gene expression control.
PPARγ coactivator-1α (PGC-1α) and -β are potent transcrip-
tional coactivators of nuclear receptors and other transcription
factors (Knutti and Kralli, 2001; Puigserver and Spiegelman,
2003; Scarpulla, 2002). They can control specific metabolic
pathways, especially oxidative metabolism, in a variety of tis-
sues. PGC-1α targets promoters by interacting directly withCELL METABOLISM : APRIL 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEVnumerous DNA binding transcription factors and then coordi-
nating several biochemical events, including recruitment of
chromatin modifying enzymes such as p300/CBP and SRC-1
(Puigserver et al., 1999), interaction with the basal transcription
machinery (Wallberg et al., 2003), and linking of transcription
to RNA splicing (Monsalve et al., 2000). The outcome is robust
activation of gene expression in coherent metabolic pathways.
PGC-1β, identified by virtue of sequence homology to PGC-
1α, has a similar tissue distribution as PGC-1α and coactivates
an overlapping but not identical repertoire of transcription
factors (Kressler et al., 2002; Lin et al., 2002a; Lin et al., 2003).
In the liver, for instance, PGC-1α docks HNF4α and FOXO1
(Lin et al., 2003) and activates gluconeogenesis, while PGC-1β
activates lipid biosynthesis by docking SREBP (Lin et al.,
2005).
One of the primary effects of PGC-1α is the activation of
mitochondrial biogenesis and oxidative phosphorylation. In
brown fat, cold exposure induces PGC-1α expression, which
leads to mitochondrial proliferation, uncoupling of oxidative
phosphorylation through increased expression of UCP-1, and
energy dissipation in the form of heat (Lin et al., 2004; Puig-
server et al., 1998). In skeletal and cardiac muscle cells, forced
expression of PGC-1α in vitro activates mitochondrial biogene-
sis, oxidative phosphorylation, and respiration (Lehman et al.,
2000; St-Pierre et al., 2003). Forced expression of PGC-1α in
type II skeletal muscle fibers in vivo leads to mitochondrial pro-IER INC. DOI 10.1016/j.cmet.2005.03.002 259
A R T I C L Eliferation and switching to more oxidative (type IIa and I) fibers
that resist fatigue from repeated electrical stimulation (Lin et
al., 2002b). Marked overexpression of PGC-1α in cardiac mus-
cle in vivo leads to mitochondrial proliferation to such an extent
that the myofibrillar contractile apparatus is displaced, leading
to cardiomyopathy and congestive heart failure (Lehman et al.,
2000). Temporally limiting PGC-1α overexpression to the adult
heart results in reversible contractile dysfunction through un-
clear mechanisms (Russell et al., 2004). Taken together, these
gain-of-function experiments have demonstrated the capacity
of PGC-1α to activate the full programs of mitochondrial bio-
genesis and oxidative phosphorylation in both skeletal and
cardiac muscle beds.
Expression of PGC-1α in muscle beds is itself highly modu-
lated, consistent with a role in cellular adaptation to environ-
mental stimuli. Chronic exercise leads to increased PGC-1α
mRNA in skeletal muscle, followed by an increased mitochon-
drial content, resistance to fatigue, and presence of more oxi-
dative fibers (Baar et al., 2002; Russell et al., 2003; Terada et
al., 2002; Wu et al., 2002). Conversely, levels of PGC-1α and
genes of mitochondrial metabolism are decreased in skeletal
muscle of diabetic patients, as well as prediabetic family mem-
bers, arguing for an early and perhaps causal role of this path-
way in the pathogenesis of type 2 diabetes (Mootha et al.,
2003; Patti et al., 2003). In the heart, PGC-1α expression is
induced perinatally and then in the adult heart, which has led
to the hypothesis that PGC-1α regulates the burst of mito-
chondrial biogenesis also observed perinatally (Lehman and
Kelly, 2002b). Pathologically hypertrophied hearts, modeled by
surgical constriction of the aorta, have decreased expression
of both PGC-1α and its target genes of fatty acid oxidation and
oxidative phosphorylation (Barger et al., 2000; Garnier et al.,
2003; Lehman and Kelly, 2002b). Similarly, overexpression of
either HDAC5 (Czubryt et al., 2003) or cyclinT1 (Sano et al.,
2004) in the heart leads to PGC-1α downregulation, mitochon-
drial dysfunction, and profound heart failure, suggesting a role
for diminished PGC-1α in the development of heart failure.
These experiments have suggested that PGC-1α in different
muscle beds can coordinate levels of energy production with
mechanical energy needs and that aberration of that balance
can lead to dysfunction and disease.
Here, we investigate whether PGC-1α is required for proper
mitochondrial function, energy generation, and contractile func-
tion in skeletal and cardiac muscle. Using PGC-1α knockout
(KO) mice, we show that, while PGC-1α is required neither for
mitochondrial biogenesis per se nor for differentiation of oxida-
tive skeletal muscle fibers, the absence of PGC-1α leads to
reduced mitochondrial function and profound defects in the
ability of the heart to respond to increased demand.
Results
Normal tissue structure and mitochondrial biogenesis
in the absence of PGC-1α
PGC-1α KO mice were generated by homologous recombina-
tion (Lin et al., 2004). The mice are very cold sensitive, consis-
tent with a role for PGC-1α in adaptive thermogenesis. They
are also lean and hyperactive, associated with defects in the
striatal part of the brain (Lin et al., 2004).
At 3 months, ratios of heart weight to tibial length, often in-
creased in the presence of cardiac structural abnormality, were260slightly lower in KO than in wt mice (Figure 1A). Hearts from
KO mice showed no histological evidence of hypertrophy or
dilatation on low-power views, nor of increased fibrosis on high
magnification views of Trichrome stainings (Figures 1B and
1C), both common cardiac mechanisms of compensation in
disease. Isolated cardiomyocytes also did not show evidence
of hypertrophy (see Figure S1A in the Supplemental Data avail-
able with this article online). In skeletal muscle, fibers were of
normal size and revealed no gross structural abnormalities
(Figure 2A). Hence, at 3 months, PGC-1α KO mice show no
overt histological signs of abnormalities in these muscle beds.
PGC-1α can activate the full program of mitochondrial bio-
genesis in vitro and in vivo (Lehman et al., 2000; Puigserver et
al., 1998; St-Pierre et al., 2003; Wu et al., 1999). Moreover,
PGC-1α gene expression in the heart is sharply increased at
the time of birth, coinciding with a sudden increase in mito-
chondrial biogenesis (Lehman et al., 2000). This has led to the
hypothesis that PGC-1α dictates, at least in part, mitochondrial
biogenesis in vivo. We tested this by examining mitochondria
in cardiac and skeletal muscle by electron microscopy (EM).
Surprisingly, only subtle differences were notable between
mitochondria from KO and wt mice in either cardiac or skeletal
muscle (Figures 1D and 1E, respectively). In the heart, the mito-
chondria appeared slightly less well packed between myofi-
bers, and slight dilation of cristae was sometimes noted (Figure
1D and data not shown). Importantly, however, the overall vol-
ume content of mitochondria appeared unchanged in KO mice.
Morphometric quantification of mitochondrial volume con-
firmed that approximately one third of the heart is taken up by
mitochondria, and no difference was seen between wt and KO
mice (Figure 1D). Thus, despite the ability of PGC-1α to acti-
vate the full program of mitochondrial biogenesis in vitro and
in vivo, PGC-1α is not required for mitochondrial biogenesis
in vivo in cardiac and skeletal muscle.
Skeletal muscle fiber types in the absence of PGC-1α
Mammals adjust to chronically increased mechanical energy
needs (e.g., exercise) by converting some glycolytic skeletal
muscle fibers into more oxidative fibers (Berchtold et al., 2000).
The latter are rich in mitochondria and contain myofibrillar pro-
teins that are more conducive to sustained work output (Hood,
2001). The mechanism by which this conversion occurs re-
mains incompletely understood, but the current evidence sug-
gests that it involves, at least in part, the induction by cAMP
and Ca2+ of PGC-1α, which then activates transcriptional pro-
grams of fiber type switching and mitochondrial biogenesis
(Czubryt et al., 2003; Handschin et al., 2003; Lin et al., 2002b;
Wu et al., 2002). Ectopic expression of PGC-1α in vivo in gly-
colytic (type IIb) skeletal myofibers is sufficient to drive fiber
switching to a phenotype with morphology and functional char-
acteristics of more oxidative types (I and IIa) (Lin et al., 2002b).
Whether PGC-1α is necessary for this process in vivo, how-
ever, is not known.
Compared to wt mice, PGC-1α KO mice are hyperactive and
move more throughout the day, in effect constantly “exercis-
ing” (Lin et al., 2004). From this aspect, one might expect that
skeletal muscle from KO mice would contain more oxidative
fibers in response to the increased energy demands and neu-
ronal stimulation. On the other hand, if PGC-1α were indeed
necessary for differentiation to more oxidative fibers, one
would predict fewer (if any) type I and IIa fibers in the KO mice.CELL METABOLISM : APRIL 2005
PGC-1α controls the energy state of cardiac muscleFigure 1. Normal tissue structure and mitochondrial biogenesis in the absence of PGC-1α
PGC-1α wt and KO mice were harvested at 3 months.
A) Body weight (BW), heart weight (HW), and ratios of heart weight to body weight (HW/BW) and tibial length (HW/TL). Error bars are ±SEM.
B) Low-power views after H&E staining of transverse sections from wt and KO hearts.
C) High magnification views of H&E (left panels) and Trichrome (right panels) stainings from the same sections as in (B).
D) Electron microscopy (8000×) photographs of longitudinal anterior sections from wt (top panels) and KO (lower panels) hearts. Morphometric quantification of
mitochondrial volume from 10 wt and 15 KO electron micrographs is shown on the right.
E) Low-power electron microscopy photographs of transverse sections form wt and KO quadriceps muscle. Morphometric quantification of mitochondrial volume from
samples of 11 wt and 8 KO electron micrographs is shown on the right.To test these possibilities, fiber type composition in skeletal
muscle was evaluated in PGC-1α KO mice by metachromatic
staining and immunocytochemistry, which allows for the dis-
tinction of type I, IIa, and IIb fibers. As seen in Figure 2, there
were no obvious differences between wt and KO mice in fiber
type composition: the soleus muscle, a type I-rich (red) muscle,
was of equal size (data not shown) and had equal numbers of
type I, IIa, and IIb fibers in KO and wt mice. Consistent with
this, expression of genes normally enriched in oxidative fibers
(such as troponin I slow, SERCA2, and sarcolipin) was similar
in soleus muscle from wt and KO mice (data not shown). Inter-
estingly, expression of these genes was slightly but signifi-
cantly (about 2-fold) elevated in KO quadriceps, a type IIb-rich
muscle (Figure 2C). This is consistent with the notion that hy-
peractivity in KO mice leads to a slight induction of oxidativeCELL METABOLISM : APRIL 2005fiber type genes. Hence, despite its ability to induce type I and
IIa fiber formation when expressed ectopically, PGC-1α is not
absolutely necessary for oxidative fiber formation in vivo.
Deficient mitochondria in skeletal and cardiac muscle
from PGC-1α KO mice
Having normal mitochondrial number does not necessarily in-
dicate normal mitochondrial function. To test if there is an ab-
normal pattern of gene expression in KO mice, we used RNA
from skeletal and cardiac muscle, combined with microarray
analyses and quantitative real-time PCR. These data (Figure 3A
and Figure S1B) revealed that the majority of the most highly
expressed genes necessary for mitochondrial function, such
as subunits of ATP synthase (e.g., atp5i and atp5c1) and cyto-
chrome c oxidase (e.g., cox5b and cox7a2), are reduced by261
A R T I C L EFigure 2. Skeletal muscle fiber types in the absence of PGC-1α
A) Immunocytochemical staining of type I β-myosin heavy chain (MHC, top panel), metachromatic ATPase staining (middle panel), and standard H&E staining (bottom
panel) of transverse sections from wt and KO soleus muscle. Asterisks indicate examples of type I fibers.
B) Fraction of type I and IIa fibers in WT and KO soleus muscle, as determined by counting fibers in complete transverse sections from both sides of two WT and two
KO mice. Error bars are ±SEM.
C) mRNA expression of genes, normally enriched in type I fibers, in quadriceps (type I-poor) muscle from three wt and three KO mice, as assayed by real-time
quantitative PCR. *p < 0.05. Error bars are ±SEM.20%–50% in skeletal muscle from KO mice. A comparison with
cultured muscle cells ectopically expressing PGC-1α indicated
that these same genes are induced by PGC-1α (Figure 3A, left
column). Importantly, these changes in gene expression in the
KO mice were observed in the absence of significant changes
in proportion of oxidative fiber types (Figure 2).
PGC-1α KO mice have many aberrant characteristics, in-
cluding hyperactivity and increased total body MVO2 (Lin et
al., 2004), which might affect the changes in gene expression
observed. To test this, we examined cultured muscle cells iso-
lated from the whole animal, thereby removing the confounding
variables inherent to the in vivo setting. As shown in Figure 3B,
the reduced expression of genes necessary for mitochondrial
function, such as cytochrome c (cycs) or cytochrome c oxidase
subunit 5b (cox5b), is still apparent in the absence of PGC-
1α, even though these cells were isolated as satellite cells and
differentiated in culture many days. These data strongly sug-
gest that these decreases in gene expression in muscle are262cell autonomous, i.e., do not depend on the whole animal KO
environment. In contrast, the type I fiber-specific genes that
were induced in whole animal skeletal muscle, such as tro-
ponin I slow (tnis) and calsarcin (Figure 2C), were not induced
in primary cells from wt and KO mice (Figure 3B), consistent
with the notion that the induction of these genes in vivo reflects
a neurohormonal response rather than a cell-autonomous phe-
nomenon.
Decreases in expression of genes relating to mitochondrial
biology were even more marked in the heart (Figure 3C). Quan-
titative real-time PCR demonstrated a 30%–50% reduction in
the expression of genes of oxidative phosphorylation, fatty acid
oxidation, and ATP synthesis (Table 1 and data not shown). West-
ern blotting with antibodies against products of two of these
genes (cytochrome c and ND4L, a member of the NADH dehy-
drogenase complex) showed significant reductions in protein
levels (Figure S1D). The expression of many of these same
genes, such as cycs or cox5b, is reduced to a similar extent inCELL METABOLISM : APRIL 2005
PGC-1α controls the energy state of cardiac muscleFigure 3. Deficient mitochondria in skeletal muscle from PGC-1α KO mice
A) Representative Affymetrix microarray analysis of mRNA from wt and KO quadriceps muscle (left panel) and from C2C12 cells infected with adenovirus encoding for
PGC-1α or GFP (right panel). The 25 mitochondrial genes that are most highly expressed in quadriceps muscle are shown. Red and green colors indicate increased
and decreased expression, respectively.
B) mRNA expression of representative genes of mitochondrial biology (cycs, ndufc1, cox5b, atp5i) and genes normally enriched in type I fibers (troponin I slow,
calsarcan) in differentiated primary skeletal cells harvested from quadriceps (type I-poor) muscle from wt and KO mice. *p < 0.05. Error bars are ±SEM.
C) Representative Affymetrix microarray analysis of total RNA from wt and KO hearts. The 20 most highly expressed and decreased genes are shown. Color coding is
as in (A). Statistical analysis of mitochondrial gene expression in the entire microarray is presented in Figure S1C.
D) Enzymatic activity in extracts from wt and KO hearts (n = 5 and 5). CS, citrate synthase. COX, cytochrome c oxidase. CII, electron transport chain complex II. LDH,
lactate dehydrogenase. Error bars are ±SEM.a well-established model of cardiac hypertrophy generated by
constriction of the transverse aorta (Table 1), as has been
shown before (Barger and Kelly, 2000; Lehman and Kelly,
2002a; Weinberg et al., 2003). In addition, the expression of a
number of transcription factors known to act in a positive feed-
back loop with PGC-1α, including PPAR-α and ERR-α (Huss
et al., 2004; Mootha et al., 2004), was also decreased (Table 1)
in KO mice, likely contributing to the reduction of target gene
expression. PGC-1α has also been shown to increase the ex-
pression of the transcription factor TFAM (Wu et al., 1999),
which in turn translocates to the mitochondria and mediates
both transcription and replication of the mitochondrial genome
(Kelly and Scarpulla, 2004). As shown in Table 1, the expres-
sion of TFAM is reduced by 50% in PGC-1α KO hearts. Con-
sistent with this, expression of genes encoded by the mito-CELL METABOLISM : APRIL 2005chondrial DNA (such as cybmm and ND5, Table 1) and the
amount of mitochondrial DNA itself (Figure S1E) are both also
reduced in KO hearts. Taken together, these data demonstrate
that PGC-1α is required for normal expression of genes relating
to mitochondrial biology in skeletal and cardiac muscle in vivo.
To test if these changes in gene expression result in corre-
sponding functional deficiencies, select enzymatic activities in
cardiac extracts were assayed. Cytochrome c oxidase (COX),
a key enzyme in electron transport and oxidative phosphoryla-
tion, and citrate synthase (CS), the rate-limiting enzyme in the
Krebs cycle, both showed more than 30% reduced activity in
hearts from KO mice (Figure 3D). Interestingly, complex II of
the electron transport chain (CII), which is made up of subunits
encoded only by the nuclear genome, was not diminished in
the KO hearts. As comparison, the activity of the cytoplasmic263
A R T I C L ETable 1. Gene expression in wt and PGC-1α KO hearts
PGC-1α KO versus wt TAC versus sham
Fold ind. p value Fold ind. p value
cycs 0.55 0.01 0.81 0.14 Oxidative phosphorylation (encoded by nucleus)
cox5b 0.59 0.005 0.61 0.02
atp5o 0.48 0.005 0.64 0.06
ndufb5 0.44 0.002 0.78 0.003
cybmm 0.50 0.017 nd nd Oxidative phosphorylation (encoded by mitochondria)
ND1 0.70 0.11 nd nd
ND5 0.50 0.021 nd nd
MCAD 0.48 0.06 0.76 0.10 Fatty acid oxydation
CPT-1 0.65 0.22 0.69 0.07
CPT-2 0.67 0.03 nd nd
CD36 0.71 0.20 nd nd
TFAM 0.55 0.047 nd nd Transcription regulation
ERR-α 0.72 0.07 nd nd
PPAR-α 0.60 0.11 nd nd
PPAR-γ 1.03 0.98 nd nd
NRF-1 0.87 0.35 nd nd
NRF-2a 0.90 0.34 nd nd
ANP 7.5 0.005 18.0 0.0002 Cardiac stress
BNP 2.1 0.06 2.2 0.23
α-MHC 1.6 0.009 0.7 0.03
β-MHC 2.6 0.06 11.9 0.001
sk α-actin 13.5 0.004 7.2 0.008
hsp70 2.8 0.58 2.6 0.09
SERCA 2a 1.1 0.37 0.7 0.002
Fold induction of gene expression in KO hearts (n = 3) over that in wt hearts (n = 3) from 3-month-old mice is shown in the left columns. For comparison, fold induction
of the same genes in hearts from same-age mice subjected to 1 month of transverse thoracic aortic banding (TAC, n = 5) over that in sham-treated hearts (n = 5) is
shown in the right columns. TAC hearts were kindly provided by Dr. Richard Lee.enzyme lactate dehydrogenase (LDH) was slightly increased
(Figure 4C), consistent with changes in LDH gene expression
(data not shown).
Defective function in isolated hearts
from PGC-1α KO mice
Given the high requirement of the heart for ATP and the defici-
encies in gene expression and mitochondrial enzymatic activi-
ties observed, we asked whether PGC-1α KO mice have al-
tered contractile function. To do this, isolated and perfused
hearts (Langendorff preparations) were used. For these experi-
ments, hearts are explanted and perfused ex vivo, allowing
regular contractions to continue. A balloon is inserted into the
left ventricle and expanded to fill the cavity, and the pressure
within the balloon is continuously measured. This allows pre-
cise evaluation of pressures and rates of pressure change dur-
ing each (now isovolumic) contraction. As stated earlier, KO
mice are lean, hyperactive, and have a highly altered glucose/
insulin axis (Lin et al., 2004). Using the well-established Lan-
gendorff preparations therefore allowed us to define the con-
tractile properties of the hearts independent of confounding
variables present in the whole-body setting, such as available
substrates or neurohormonal environment.
Using this approach, hearts from 3-month-old PGC-1α KO
mice revealed small but significant contractile deficiencies
when allowed to spontaneously pump without further stimulus
(Table S1A): both the rate of change of pressure during con-
traction (+dP/dt) and the maximal achieved pressure (LVSP)
were reduced about 10% (p < 0.05). These deficiencies, how-
ever, became more pronounced under stimulation (Table S1A
and Figure 4A). For example, isolated hearts can be made to264beat at higher rates by apposing an electrode directly onto the
heart and pacing at an increased frequency. This purely chro-
notropic challenge in KO hearts led to 20% less forceful con-
tractions (+dP/dt) than in wt hearts (Table S1A). When the
hearts were forced to abruptly increase work by infusion with
dobutamine (a β-adrenergic agonist that leads to large in-
creases in both heart rate and force of contraction, i.e., both
a chronotropic and inotropic challenge), +dP/dt in wt hearts
increased by 30% more than in KO hearts (Figure 4A and Table
S1A). A similar pattern of mild baseline deficiency and worsen-
ing under stimulation was noted for the parameter that reflects
measured relaxation (−dP/dt), a process that also requires en-
ergy (restoring the Ca2+ gradient). Interestingly, KO hearts also
showed a significant inability to increase heart rate in response
to dobutamine (Table S1A). Lower heart rate can increase +dP/
dt; hence, the deficiency in +dP/dt seen here probably under-
estimates the true magnitude of deficiency in KO hearts. A bet-
ter index of cardiac work, therefore, is the rate pressure prod-
uct (RPP), equal to heart rate times the increase in pressure
developed by each contraction (DevP). As seen in Figure 4B,
wt hearts can increase RPP by nearly twice as much as can
KO hearts in response to dobutamine.
In the experiments described above, hearts were perfused
with modified Krebs bicarbonate buffer, which contains glu-
cose and pyruvate as energy sources. However, the heart uses
primarily free fatty acids as a carbon source in vivo (Ingwall,
2003). Moreover, PGC-1α is well-known to activate genes of
fatty acid import and oxidation, and expression of these genes
is decreased in PGC-1α KO hearts (Table 1). We therefore also
measured the contractile function of wt and KO hearts per-
fused with a buffer containing physiological concentrations ofCELL METABOLISM : APRIL 2005
PGC-1α controls the energy state of cardiac muscleFigure 4. Defective cardiac function in PGC-1α KO mice
A) Contractile performance of hearts from PGC-1α KO (red, n = 5) compared to wt (blue, n = 5) hearts measured in Langendorff preparations. Hearts were electrically
paced at 7.0 Hz. After 10 min, hearts were challenged with 300 nM dobutamine for 12 min and then allowed to recover for another 15 min. +dP/dt, positive change in
pressure over time during isovolumic contraction. −dP/dt, negative change in pressure over time during isovolumic relaxation. RPP, rate pressure product = heart rate
times pressure differential between the fully contracted and relaxed states. RPP models the work done by the heart in vivo.
B) Rate pressure product in wt and KO hearts at baseline and in response to dobutamine. In the top panel, hearts from wt (n = 5) and KO (n = 5) mice were perfused
with modified Krebs bicarbonate buffer containing glucose and pyruvate. In the bottom panel, hearts from wt (n = 4) and KO (n = 4) mice were perfused with buffer
containing physiological concentrations of free fatty acids, glucose, lactate, and ketones, as described in Experimental Procedures. Error bars are ±SEM.all carbon sources normally used by the heart: free fatty acids,
glucose, ketones, and lactate. Under these conditions, the
contractile deficiencies of the KO hearts became even more
pronounced (Table S1B). In response to dobutamine, for in-
stance, the RPP increased only 30% as much in KO hearts as
it did in wt hearts (Figure 4C and Table S1B). Together, these
data show that hearts from PGC-1α KO mice have a profound
defect in contractile reserve, suggesting that PGC-1α is vital
to increasing cardiac work output in response to increased
demand.
Hearts from PGC-1α KO mice are energy deficient
The KO hearts were next studied for their ability to maintain
readily available sources of energy for mechanical work. The
ATP content of wt and KO hearts was measured by 31P nuclear
magnetic resonance (NMR) using the Langendorff heart prepa-
rations (Figure 5A). From these measurements, concentrations
of ATP, inorganic phosphate (Pi), and phosphocreatine (PCr)CELL METABOLISM : APRIL 2005can be calculated from the area under each peak. PCr, the
primary energy reserve compound in excitable tissues, is nor-
mally present in cardiac muscle at twice the concentration of
ATP and is in rapid exchange with ATP; an accurate measure
of available high-energy phosphate bonds thus requires eval-
uation of both ATP and PCr concentrations. The most powerful
advantages of this NMR technique stem from its ability to non-
invasively measure ATP and PCr contents in intact, beating
hearts under differing conditions and while simultaneously
measuring contractile performance.
Using this approach, we found that ATP levels in unstimu-
lated PGC-1α KO hearts were reduced by approximately 20%
compared with wt hearts (Figures 5A and 5B and Figure S2A).
The concentration of ATP in cardiac tissue is normally tightly
controlled and, in cases of terminal heart failure, is reduced by
only approximately 30%. Hence, the absence of PGC-1α re-
sults in a profound energetic defect in the heart. Similarly, the
concentration of PCr was also reduced by w20% (Figures 5A265
A R T I C L EFigure 5. Hearts from PGC-1α KO mice are energy deficient
A) Representative spectra acquired from wt and KO hearts during active, unstimulated contraction. Peaks corresponding to signals from the phosphorus atoms in
each of the phosphates of ATP and phosphocreatine (PCr), and free inorganic phosphate (Pi) are indicated.
B) Average ATP and PCr concentrations in wt and KO hearts that are either unstimulated or maximally stimulated with 300 nM dobutamine infusion, as assayed from
NMR spectra as in (A). N = 5 and 5. Error bars are ±SEM.
C) Relationship, in wt and KO hearts, between the rate pressure product (RPP, a measure of cardiac work) and GwATP (representing the driving force available from
ATP hydrolysis). Note that, at baseline, both KO and wt hearts generate similar amounts of work for a similar GwATP, while, under dobutamine stimulation, KO hearts
have markedly blunted work output for a similar drop in GwATP. Note also that both KO and wt hearts are maximally stimulated by dobutamine to the theoretical limit
for GwATP, i.e., the chemical driving force needed to drive Ca2+ into the sarcoplasmic reticulum by the SERCA channel (indicated with an arrow). Error bars are ±SEM.and 5B and Figure S2A). Interestingly, inotropic and chrono-
tropic stimulation of the hearts by dobutamine infusion resulted
in PCr depletion down to similar concentrations in both wt and
KO hearts (Figure 5B and Figure S2A).
In order to perform mechanical work, the heart requires a
sufficiently elevated chemical driving force (GwATP ), calcu-
lated from the ratio of concentrations of ATP to ADP and Pi,
the so-called phosphorylation potential ([ATP]/[ADP]*[Pi]). This
ratio reflects the free energy released from ATP hydrolysis,
which can then be used to overcome a coupled and unfavor-
able reaction. Without a sufficiently large phosphorylation po-
tential, ATP-dependent reactions such as the actomyosin
ATPase reaction and Ca2+ sequestration cannot occur. Thus,
the heart can only increase work output until GwATP approaches
the level needed by the most unfavorable coupled reaction.
In wild-type hearts, it has been estimated that this threshold
potential is that needed to drive the sarcoplasmic reticulum266Ca++ ATPase (SERCA), at a GwATP of approximately 53 kJ/
mol (Ingwall, 2002). As seen in Figure 5D, that threshold is
reached in PGC-1α KO hearts with much less work output than
in wt hearts. Thus, for a similar change in GwATP (equivalent
to about 5 kJ/mol), hearts from PGC-1α KO mice generate
much less work than do wt hearts.
Cardiac dysfunction in PGC-1α KO mice in vivo
To determine if the multiple defects described above result in
cardiac insufficiency in vivo, echocardiography was performed.
At 3 months of age, no differences between wt and KO mice
were apparent (Figure S2B). Cardiac dysfunction, however,
often becomes apparent only with age, both in mice and hu-
mans. Older mice were therefore also examined. As shown in
Figure 6A, by 7–8 months of age, PGC-1α KO mice displayed
clear features of cardiac dysfunction in vivo. Left ventricular
chamber size in KO mice was slightly more dilated, both at endCELL METABOLISM : APRIL 2005
PGC-1α controls the energy state of cardiac muscleFigure 6. Cardiac dysfunction in PGC-1α KO mice in vivo
A) Cardiac echocardiograms were performed on 7- to 8-month-old wt (n = 4), heterozygote (n = 3), and KO (n = 3) female mice. The top panel shows representative
M mode echocardiograms (in which a one-dimensional signal across the center of a transverse section of the heart is visualized over time) of wt and KO mice. The
bottom panel shows in bar graph format the normalized left ventricular anterior wall (LVAW) and posterior wall (LVPW) thicknesses, end diastolic (LVEDD) and end
systolic (LVESD) diameters, and fractional shortening (FS, calculated as LVEDD − LVESD/LVEDD). Error bars are ±SEM.
B) mRNA expression, in the same hearts as in (A), of the indicated genes as assayed by real-time quantitative PCR (top panel) and Northern blotting (bottom panel).
EtBr, ethidium bromide stain of gel prior to transfer. Error bars are ±SEM.diastole and end systole (Figure 6A). Most notably, KO mice
showed significantly reduced fractional shortening (the differ-
ence in internal diameter between the fully dilated and fully
contracted state, Figure 6A), demonstrating poor cardiac con-
traction in vivo in the absence of PGC-1α.
The 7- to 8-month-old KO mice also displayed molecular evi-
dence of cardiac stress. Hearts faced with prolonged duress
often undergo partial genetic reprogramming, with the induc-
tion of a number of so-called “fetal genes,” such as β-MHC
and skeletal α-actin (Friddle et al., 2000; Olson and Schneider,
2003). In addition, cardiac myocytes respond to stretch by in-
ducing the genes for and secretion of atrial and brain natriuretic
peptides (ANP and BNP), with the goal of reducing intravascu-
lar volume by stimulating diuresis (Cameron and Ellmers,
2003). As shown in Figure 6B, all these genes are also strongly
induced in hearts of 7- to 8-month-old PGC-1α KO mice. To-
gether, these data show that, by this later age, the defects re-
sulting from the absence of PGC-1α lead to frank cardiac dys-
function in vivo.
Interestingly, hearts from 3-month-old mice also revealed
similar molecular signs of cardiac stress, although less pro-
nounced (Table 1 and Figure S2C). In fact, circulating levels ofCELL METABOLISM : APRIL 2005pro-ANP hormone were induced 2-fold in 3-month-old KO
mice (Figure S2D), consistent with the induction of the ANP
gene in the hearts. Hence, even at 3 months of age, PGC-1α
KO hearts show clear signs of cardiac stress in vivo, consistent
with the significant energetic and contractile defects observed
in isolated heart preparations.
Discussion
The heart must maintain an unfailing blood circulation in states
of both rest and high demand, such as that triggered by exer-
cise. A trained athlete, for example, can rapidly increase
cardiac output as much as 6-fold (Baim and Grossman, 2000).
The amount of work done by the heart, therefore, must be effi-
cient, dependable, and highly adaptable. Generating this work
depends on a copious and equally adaptable supply of ATP. In
a given day, the heart can consume approximately ten times
its own weight in ATP (Ingwall, 2003; Ingwall and Weiss, 2004).
The heart therefore needs an abundant and ongoing generation
of ATP that can adapt to changing external or internal de-
mands. The bulk of this occurs through efficient oxidative
phosphorylation in mitochondria.267
A R T I C L ERecent data have suggested an important role for PGC-1α
in the control of mitochondrial metabolism of the heart, but
this has been based only on gain-of-function studies. What has
remained unclear to date is the requirement for endogenous
PGC-1α in the function of the intact heart. In this study, we
have addressed this question by studying hearts from mice
lacking PGC-1α. Measurements of cardiac gene expression
and echocardiographic indices of cardiac function in vivo were
combined with functional analyses of isolated heart prepara-
tions. The use of these Langendorff preparations allowed us to
isolate the hearts from their nutrient and hormonal milieu,
which was crucial because mice lacking PGC-1α demonstrate
a profound hyperactivity and an altered glucose/insulin axis
(Lin et al., 2004). We show here that the absence of PGC-1α
leads to blunted mitochondrial enzymatic activity and frankly
decreased levels of ATP in the heart. In the face of this ener-
getic defect, hearts from PGC-1α KO mice are unable to nor-
mally perform the work of contraction, and KO mice eventually
develop cardiac dysfunction in vivo.
The contractile defects observed in isolated heart prepara-
tions became most pronounced when hearts were forced to
accomplish more work, such as that needed for exercise or
“fight or flight” responses. Such situations are typically trig-
gered by catecholamine surges and can be modeled ex vivo
in Langendorff preparations by stimulation with saturating
amounts of dobutamine, a potent β-adrenergic agonist. When
this was done, the synthesis of ATP in PGC-1α KO hearts was
insufficient to meet increased demand, and the energetic limit
was reached with far less physical work achieved than in wt
hearts. These data indicate that functional PGC-1α is critical
for normal ATP generation and cardiac work. Moreover, the
data suggest that the primary function of PGC-1α may be to
serve an adaptive role, equipping the heart with the enhanced
ability to respond to sudden increases in demand. This is con-
sistent with the observation that PGC-1α expression in cardiac
muscle is low before birth, when such responses are unneces-
sary, and then induced during the first few weeks of life (Leh-
man et al., 2000; Lehman and Kelly, 2002b).
It is important to note that hearts devoid of PGC-1α have
blunted responses of both contraction and heart rate in re-
sponse to dobutamine challenge. In fact, cardiac force is typi-
cally higher in the context of lower heart rates (Katz, 2001), so
the force-generating defect in KO mice may be underesti-
mated. Altered β-adrenergic signaling could be an obvious
cause for these blunted responses, but this is unlikely for sev-
eral reasons: first, dobutamine stimulation causes similar
change in the chemical driving force for ATPase reaction, i.e.,
energy drain, in both KO and wt hearts; second, the functional
defects of KO hearts are also exacerbated by pacing at ele-
vated heart rates; third, expression of genes of β-adrenergic
signaling such as the β receptors or βARK are not altered in KO
mice (Figure S2E). Why the response of heart rate is blunted in
PGC-1α KO hearts is unclear. Much of the regulation of heart
rate in vivo is neurohormonal (Katz, 2001), but, in Langendorff
preparations, the hearts are no longer under this control.
Hence, PGC-1α appears to be required for maximal automatic-
ity of pacemaker cells. This may occur due to bioenergetic in-
sufficiency, but it is also possible that the absence of PGC-
1α leads to defects in heart rate (and/or contraction) through
mechanisms not involving the mitochondria. Further experi-
mentation on this point will be needed.268That the cardiac defects observed in the Langendorff prepa-
rations have physiological relevance in vivo is indicated by the
molecular changes observed in 3-month-old hearts, including
induction of ANP, β-MHC, and skeletal α-actin (Table 1). More-
over, mice lacking PGC-1α go on, by 8 months of age, to de-
velop enlargement of left ventricular chamber size and dimin-
ished contractile function (Figure 6). At the same time, no
evidence of cardiac hypertrophy is seen (Figures 1 and 6, Fig-
ure S1A), suggesting that this phenotype is more akin to that
of primary dilated cardiomyopathy than to dilation secondary
to hypertrophic cardiomyopathy. It is likely that the phenotype
will deteriorate with age. It will also be interesting to determine
if the lack of PGC-1α will impair cardiac adaptation to specific
long-term stressors, such as exercise or surgical constriction
of the aorta. Unfortunately, PGC-1α KO mice have other phe-
notypes, including hyperactivity and an aberrant insulin/glu-
cose axis (Lin et al., 2004), making it difficult to evaluate in a
well-controlled fashion the cardiac response to exercise in
whole mice. A critical evaluation of the role of PGC-1α in
cardiac function in intact animals will thus require the cardiac-
specific knockout of PGC-1α.
Physical activity induces PGC-1α expression in skeletal
muscle tissue (Baar et al., 2002; Terada et al., 2002; Wu et al.,
2002), and PGC-1α induces muscle fiber type switching to
more oxidative fibers when expressed in transgenic mice (Lin
et al., 2002b). On this basis, one might have expected a de-
crease of such fibers in PGC-1α KO mice. We show here, how-
ever, that in the absence of PGC-1α there is no obvious de-
crease in oxidative fibers in skeletal muscle (Figure 2). In fact,
in quadriceps muscle, which is primarily glycolytic in nature,
there is a 2- to 3-fold induction of genes specific to oxidative
fibers (Figure 3B), although no frank increase in oxidative fibers
was noted in primarily glycolytic muscle such as extensor digi-
torus longus (data not shown). This increase is not observed in
isolated skeletal muscle cells from KO versus wt mice, sug-
gesting that the difference is not cell autonomous (Figure 3B).
These observations are most consistent with the notion that
the hyperactivity of KO mice causes an increased motor nerve
input to skeletal muscle that is sufficient to activate the expres-
sion of genes characteristic of oxidative fibers. Importantly,
these data also demonstrate that mitochondria and oxidative
fibers can form without the presence of PGC-1α. Since PGC-
1β can also stimulate mitochondrial biogenesis and respiration
when expressed ectopically (St-Pierre et al., 2003), it is plausi-
ble that PGC-1β may be compensating for the absence of
PGC-1α in both mitochondrial and oxidative fiber formation
in vivo. It is also possible that PGC-1α plays a more prominent
role in adaptive responses to physical exercise, rather than the
basal profiles of mitochondria or fiber types. Clearly, an under-
standing of how the absence of PGC-1α affects muscle fiber
type formation in mice with comparable levels of physical
movement will require skeletal muscle-specific KO of PGC-1α.
The notion that energy “starvation” is a significant contrib-
utor to the pathogenesis of cardiac failure has long been enter-
tained (Ingwall and Weiss, 2004). The work described here
lends significant support to this hypothesis: the absence of
PGC-1α causes a decrease in available ATP supply and leads
to significant contractile defects. Indeed, significant drops in
PGC-1α transcript levels have been observed in various rodent
models of cardiac failure (Czubryt et al., 2003; Feingold et al.,
2004; Garnier et al., 2003; Lehman and Kelly, 2002b; Sano etCELL METABOLISM : APRIL 2005
PGC-1α controls the energy state of cardiac muscleal., 2004). The results presented here thus support the idea
that stimulation of PGC-1α activity represents a potential new
therapeutic modality. Indeed, ectopic expression of PGC-1α in
skeletal muscle can improve indices of fatiguability (Lin et al.,
2002b). While massive overexpression of PGC-1α in normal
hearts leads to cardiomyopathy (Lehman et al., 2000; Russell
et al., 2004), increasing the expression of active PGC-1α at
more physiological levels might improve contractile function in
failing hearts.
Experimental procedures
Animals
All animal experiments were performed according to procedures approved
by the Institutional Animal Care and Use Committee. Mice were maintained
on a standard rodent chow diet with 12 hr light and dark cycles. Frozen
heart samples from 3-month-old mice 1 month after sustaining banding of
their aorta were kindly provided by Dr. Richard Lee (Weinberg et al., 2003).
Cells and reagents
C2C12 cells were from ATCC and were grown in DMEM 10% FBS and
differentiated for 5 days in DMEM 4% HS prior to adenoviral infection. Pri-
mary skeletal muscle cells were harvested as published (Sabourin et al.,
1999) and grown and differentiated as above. Left ventricular cardiomyo-
cytes were isolated as described (Matsui et al., 2002; Nagata et al., 2000).
Cell surface was determined using NIH image. Adenovirus-expressing
PGC-1α has been published (Puigserver et al., 1998). Pro-ANP assays were
performed using the kit from ALPCO Diagnostics following the included
protocol. Antibodies against cytochrome c and ND4L were from Phar-
mingen and Santa Cruz, respectively.
Histological analyses
Tissues for regular histology were frozen in liquid nitrogen immediately upon
mouse sacrifice. Cardiac H&E and Trichrome stains were performed by
American HistoLabs. Tissues for fiber type evaluation were embedded in
gum tragacanth and OCT freezing matrix and quickly frozen in isopentane
cooled in liquid nitrogen. Fiber typing was performed with cryostat sections
using metachromatic dye-ATPase methods as described (Ogilvie and Fee-
back, 1990). Immunohistochemical staining was performed with a monoclo-
nal antibody against skeletal slow myosin (NOQ7.5.4D, Sigma).
Genetic expression studies
Total RNAs were isolated from mouse tissue or cultured cells using the
TRIzol method (Invitrogen). For microarray analyses, skeletal muscle and
cardiac RNAs were evaluated with Affymetrix U74v2 and 430A chips,
respectively, using the DFCI core facility. All subsequent analyses were per-
formed with dCHIP software. For Northern analyses, 10 µg of RNA were
separated on a formaldehyde gel, transferred to nylon membrane, and hy-
bridized with probes amplified by PCR from genomic DNA. Samples for
real-time PCR analyses were reverse transcribed (Invitrogen), and quantita-
tive real-time PCR reactions were performed on the cDNAs in the presence
of fluorescent dye (Cybergreen, Bio-Rad). DNA product of the expected size
was confirmed for each primer pair.
Langendorff preparations
Mice were heparinized (100 units, IP) 15 min before being sacrificed. Hearts
were isolated and perfused in the Langendorff mode as described (Chu et
al., 1996). Hearts were perfused either with modified Krebs bicarbonate
buffer containing pyruvate (0.5 mM) and glucose (10 mM) or with buffer
containing physiological concentrations of mixed free fatty acid (0.4 mM)
(palmitate, palmitoleic, linoleic, and oleic) carried in 1% BSA, glucose (5.5
mM), β-hydroxybutarate (0.19 mM), and lactate (1.0 mM). The composition
of this mixture was chosen based on literature reports (Previs et al., 1999;
Rofe et al., 1985) and direct measurements of substrate concentrations in
the plasma of mice (data not shown). A water-filled balloon was then in-
serted into the left ventricle (LV) and inflated to LV end diastolic pressure of
10 mmHg. Isovolumic contractile performance data were collected online
at a sampling rate of 200 Hz. Baseline measurements were made after a 20
min stabilization period (equivalent for all experiments and both genotypes).CELL METABOLISM : APRIL 2005The hearts were then paced at 7.0 Hz using monophasic square wave
pulses delivered from a stimulator (model S88; Grass Instrument Co.,
Quincy, MA) through salt bridge pacing wires consisting of PE-90 tubing
filled with 4 M KCl in 2% agarose. The hearts were then challenged with
300 nM of dobutamine infused through a side tubing driven by a digital
console driver (Cole-Parmer Instrument Co.) at 2% of coronary flow rate.
31P NMR spectroscopy
31P NMR spectra were obtained at 161.94 MHz using a GE-400 wide-bore
spectrometer (Omega, General Electric, Fremont, CA). The isolated per-
fused hearts, in a 10 mm NMR sample tube, were inserted into a 1H/31P
double-tuned probe situated in a 89 cm bore, 9.4 T superconducting mag-
net. Spectra were collected during 8 min periods and consisted of data
averaged from 208 free induction decays as described (Chu et al., 1996;
Spindler et al., 1998). 31P NMR spectra were analyzed using 20 Hz expo-
nential multiplication and zero and first-order phase corrections. The reso-
nance areas corresponding to ATP, PCr, and Pi were fitted to Lorentzian
functions and corrected for saturation (ATP [1.0], PCr [1.2], and Pi [1.15]).
The changes in concentration of ATP, PCr, and Pi during the protocols were
calculated as described (Spindler et al., 1998). The free energy released by
ATP hydrolysis (GwATP) is calculated as GwATP = G° + RT ln
([ADP][Pi]/[ATP]).
Biochemical assays
Cardiac ventricular tissue was homogenized in potassium phosphate buffer
containing 1 mM EDTA and 1 mM β-mercaptoethanol (pH 7.4). Aliquots
were removed for assays of protein (Lowry et al., 1951) and total creatine
content (Kammermeier, 1973). Triton X-100 was then added to the homoge-
nate at a final concentration of 0.1%, and the activities of citrate synthase
(Srere et al., 1963), cytochrome C oxidase (Stieglerova et al., 2000), and
electron transport chain complex II (Makita and Sagara, 1990) were mea-
sured as described.
Echocardiographic analyses
Transthoracic echocardiography was performed using a 15 Mhz linear-array
probe and a Sonos 4500 ultrasonograph (Hewlett Packard). The images
were taken in 2K (left parasternal long and short axes) and M mode (left
parasternal short axis). All echocardiograms were performed blinded to the
mouse genotype. LV fractional shortening was calculated using the formula
LVEDD − LVESD/LVEDD.
Statistical analysis
All results are expressed as means ±SEM. Two-tailed independent Stu-
dent’s t tests were used to determine all p values.
Supplemental data
Supplemental data include two figures and one table and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/1/4/259/
DC1/.
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